Literature DB >> 15064694

Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors.

A Schattenberg1, A van der Meer, F Preijers, N Schaap, M Rinkes, R van der Maazen, W Allebes, I Joosten, Th De Witte.   

Abstract

We retrospectively analysed the outcome of voluntary unrelated donor (VUD)-SCT in 56 patients after conditioning without or with ATG. All received partially lymphocyte-depleted grafts. Four of 17 patients (24%) who were not given ATG rejected their grafts, as did one of 33 (3%) conditioned with ATG (P=0.02). The incidences of acute graft-versus-host disease grade III/IV were 29 and 6%, respectively (P=0.02), and probabilities of 1-year transplant-related mortality were 64% (95% CI, 44-84%) and 27% (95% CI, 12-42%), respectively (P=0.004). Projected at 3 years, probability of survival was 18% (95% CI, 2-34%) after conditioning without ATG and 60% (95% CI, 43-70%) after conditioning with ATG (P=0.002). Probabilities of disease-free survival (DFS) were 18% (95% CI, 2-34%) and 45% (95% CI, 27-63%), respectively (P=0.005). Patients who did not receive ATG had a probability of current DFS of 18% (95% CI, 3-34%) and this was 60% (95% CI, 43-77%) for the patients conditioned with ATG (P<0.001). We conclude that the addition of ATG to the conditioning regimen is associated with a significantly more favourable outcome in recipients of partially T-cell-depleted grafts from VUDs. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064694     DOI: 10.1038/sj.bmt.1704490

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

Review 1.  Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Frédéric Baron; Mohamad Mohty; Didier Blaise; Gérard Socié; Myriam Labopin; Jordi Esteve; Fabio Ciceri; Sebastian Giebel; Norbert Claude Gorin; Bipin N Savani; Christoph Schmid; Arnon Nagler
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

2.  Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Willemijn Hobo; Kelly Broen; Walter J F M van der Velden; Annelies Greupink-Draaisma; Niken Adisty; Yannick Wouters; Michel Kester; Hanny Fredrix; Joop H Jansen; Bert van der Reijden; J H Frederik Falkenburg; Theo de Witte; Frank Preijers; Ton Schattenberg; Ton Feuth; Nicole M Blijlevens; Nicolaas Schaap; Harry Dolstra
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

3.  Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation.

Authors:  Kodai Kuriyama; Shigeo Fuji; Yoshihiro Inamoto; Kinuko Tajima; Takashi Tanaka; Yoshitaka Inoue; Reiko Ito; Yoshiki Hayashi; Ayumu Ito; Saiko Kurosawa; Sung-Won Kim; Takuya Yamashita; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2016-02-09       Impact factor: 2.490

4.  Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant.

Authors:  Qaiser Bashir; Mark F Munsell; Sergio Giralt; Leandro de Padua Silva; Manish Sharma; Daniel Couriel; Alexandre Chiattone; Uday Popat; Muzaffar H Qazilbash; Marcelo Fernandez-Vina; Richard E Champlin; Marcos J de Lima
Journal:  Leuk Lymphoma       Date:  2011-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.